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Abstract
Purpose: Age-related macular degeneration caused by choroidal neovascularization (CNV) remains difficult to be treated
despite the recent advent of several treatment options. In this study, we investigated the in vivo angiogenic control by
intravenous injection of polyion complex (PIC) micelle encapsulating plasmid DNA (pDNA) using a mice CNV model.
Methods: The transfection efficiency of the PIC micelle was investigated using the laser-induced CNV in eight-week-old
male C57 BJ/6 mice. Firstly, each mouse received intravenous injection of micelle encapsulating pDNA of Yellow Fluorescent
Protein (pYFP) on days 1,3 and 5. The expression of YFP was analyzed using fluorescein microscopy and western blotting
analysis. In the next experiments, each mouse received intravenous injection of micelle encapsulating pDNA of soluble Fms-
like tyrosine kinase-1 (psFlt-1) 1,3 and 5 days after the induction of CNV and the CNV lesion was analyzed by choroidal
flatmounts on day 7.
Results: Fluorescein microscopy and western blotting analysis revealed that the expression of YFP was confirmed in the
CNV area after injection of the PIC micelle, but the expression was not detected neither in mice that received naked pDNA
nor those without CNV. Furthermore, the CNV area in the mice that received intravenous injection of the psFlt-1-
encapsulated PIC micelle was significantly reduced by 65% compared to that in control mice (p,0.01).
Conclusions: Transfection of sFlt-1 with the PIC micelle by intravenous injection to mice CNV models showed significant
inhibition of CNV. The current results revealed the significant potential of nonviral gene therapy for regulation of CNV using
the PIC micelle encapsulating pDNA.
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Introduction
Age-related macular degeneration (AMD) is a leading cause of
legal blindness in developed countries, and even with the recent
advent of several treatment options, treatment of AMD remains
difficult [1–2]. Vision loss in AMD occurs with the advance of
AMD, that is, ‘‘exudative’’ AMD and ‘‘geographic atrophy’’.
Visual loss in exudative AMD is caused by choroidal neovascu-
larization (CNV), i.e., the neovascular vessels extending from the
choroid underneath the sensory retina, and the subsequent
atrophy of the retinal pigment epithelium (RPE). One of the
major factors that induce CNV is vascular endothelial growth
factor-A (VEGF-A), a diffusible cytokine that promotes angiogen-
esis and vascular permeability [3]. Clinical studies have revealed
that the intravitreal administration of VEGF-A antagonists such as
ranibizumab and bevacizumab, and an RNA aptamer that
specifically inhibits the VEGF 165 isoform, i.e., pegaptanib,
arrests CNV progression and leakage, and ameliorates exudative
change and improves visual acuity [4,5,6] However, these drugs
need to be used repeatedly at 4- to 6-week intervals [4,5,6], which
raises concerns about injection-related adverse events, including
ocular inflammation, retinal injury, and endophthalmitis.
Another major approach to inhibit the VEGF signaling
pathway in CNV is the use of VEGF kinase inhibitors; however,
most of the currently developed receptor tyrosine kinase (RTK)
inhibitors are not VEGF-selective and also inhibits other RTKs,
raising the possibility of unexpected side effects [7]. A previous
study from our laboratory has demonstrated that highly VEGF-
selective RTK inhibitors are effective in reducing the size of CNV
model; however, the study demonstrated that systemic adminis-
tration of VEGF-selective inhibitors may also lead to unexpected
systemic side effects [8]. Another approach to inhibit VEGF signal
is the application of soluble VEGF receptor 1 (soluble fms-like
tyrosine kinase-1, sFlt-1). sFlt-1 is a potent endogenous molecule
and is highly specific to VEGF, and binds VEGF with the same
affinity and inhibits its signal transduction [9,10,11].
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have demonstrated that macromolecules accumulate to CNV
lesion with high efficiency through enhanced permeability and
retention (EPR) effect after intravenous injection [12–13]. As a
first step to develop a drug delivery system utilizing the EPR effect,
our group have demonstrated that biocompatible core-shell type
nanocarriers, i.e., polyion complex (PIC) micelle formed through
the electrostatic interaction between oppositely charged macro-
molecules, can achieve effective accumulation in the CNV lesion
in a mouse model [12,14]. Moreover, as a promising non-viral
vector for gene therapy, PIC micelles consisting of plasmid
DNA and poly(ethylene glycol)-b-poly{N-[N-(2-aminoethyl)-2-ami-
noethyl]aspartamide} block copolymers [PEG-b-PAsp(DET)],
which show minimal cytotoxicity and high transfection efficiency
both in vitro and in vivo [15,16,17,18,19], have been shown to be
utilized for the gene therapy against a mouse corneal neovascu-
larization model by local administration of plasmid encoding sFlt-1
[20].
In this study, we have applied the PIC micelles formed from
pDNA and the mixture of PEG-b-PAsp(DET) block copolymers
and PAsp(DET) homopolymers to the systemic injection to a mice
CNV model. Because repeated intraocular injections poses the
risks of retinal detachment and endophthalmitis on the patients, a
novel strategy to avoid repeated injection is needed. The current
study demonstrates an intriguing possibility that systemic admin-
istration of the PIC micelles can achieve effective and safe
treatment of CNV.
Results
Targeted gene expression in the CNV area after
intravenous injection of pYFP-PM
Firstly, experiments were performed to determine the efficacy of
gene expression of intravenous injection of pYFP-PM. The CNV
lesions were induced by laser photocoagulation. Subsequently,
each mouse received an intravenous injection of 200 mL of pYFP-
PM or PBS, and the expression pattern was evaluated by
fluorescent microscopy. At seven days after the injection, choroidal
flatmount and histological analysis demonstrated YFP fluorescence
in the CNV area after intravenous injection of pYFP-PM (Fig1 a).
Furthermore, Western blotting analysis demonstrated that YFP
protein was detected in the eyes with CNV, after intravenous
injection of pYFP-PM. YFP expression was detected neither after
generation of CNV alone nor after intravenous injection of pYFP-
PM without CNV (Fig1 b). Next, immunohistochemistry was
performed to examine the cells in which YFP protein expressed.
The results demonstrated that the localization of F4/80 was
partially overlapping the expression of YFP, indicating that YFP
protein expressed in F4/80-positive macrophage (Fig1 c).
Intravenous injection of psFlt-1-PM decreased the area of
CNV
The results led us to investigate the effects of the transfection of
the plasmid encoding human sFlt-1 in CNV. After CNV was
induced, mice received an intravenous injection of psFlt-1-PM or
pYFP-PM and PBS. Quantification of the CNV lesion demon-
strated that whereas the administration of pYFP-PM had no
significant effects on the area, the neovascularized area in the mice
that received an intravenous injection of psFlt-1-PM was
significantly reduced by 60% than that of control mice (n=7,
p,0.01) (Fig 2). In addition, no remarkable abnormality in the
fundus, other than at the photocoagulated sites was detected.
Systemic adverse effect
We investigated the systemic effects caused by intravenous
injection of the PIC micelles. Laboratory data, including aspartate
aminotransferase (AST), alanine aminotransferase (ALT), blood
urea nitrogen (BUN), and creatinine were within normal limits
after the venous injection of the PIC micelles (Table1).
Discussion
PEG-b-PAsp(DET) block copolymers show a remarkably high
transfection efficacy and low toxicity [15]. The PIC micelles are
Figure 1. Preparation of PIC micelles encapsulating pDNA.
doi:10.1371/journal.pone.0028560.g001
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shell structure consisting of the plasmid DNA-loaded PIC core
surrounded by the PEG shell with the sterically repulsive
propensity. Moreover, after internalization into cellular compart-
ments, PEG-b-PAsp(DET) is expected to facilitate efficient
translocation of the micelle toward the cytoplasm since the
ethylenediamine side chain of PAsp(DET) might exhibit a low pH-
selective membrane disruptive function
4. In the current study, to
investigate its potential for anti-angiogenic therapy, we have
developed the PIC micelles composed of pDNA and the mixture
of PEG-b-PAsp(DET) block copolymers and PAsp(DET) homo-
polymers for systemic gene delivery, and demonstrated that
transgene expression is achieved by intravenous injection of the
PIC micelles in CNV area. Furthermore, we demonstrated that
transfection of the PIC micelles encapsulating psFlt-1 by
intravenous injection to mice CNV models showed significant
inhibition of developing CNV.
Recently, it has been demonstrated that intravitreous injection
of VEGF-A antagonists such as ranibizumab, bevacizumab, and
pegaptanib arrests CNV progression and leakage from CNV, and
improves visual acuity [21–24]. However, these drugs need to be
used repeatedly at 4- to 6-week intervals, which raises concerns
about injection-related adverse events including ocular inflamma-
tion, retinal injury, and endophthalmitis. Intravitreal adeno-
associated virus (AAV) expressing sFlt-1 can achieve prolonged
expression in mice; however, intraocular injection of AAV was
associated with vitreal inflammation [25]. Furthermore the safety
of long-term intraocular VEGF-A neutralization remains un-
known [26,27]. Previously we have evaluated the effects of
bevacizumab and anti-rat VEGF antibody on retinal ganglion cells
both in vivo and in vitro [28]. The results demonstrated that the
short term VEGF-A neutralization showed no toxicity on retinal
ganglion cells. However, another group reported that 6-month
sustained expression of sFlt-1 in retinal pigment epithelial cells in
mice results in photoreceptor degeneration [29]. Furthermore,
several investigations report the reduction in retinal vessel
diameter and flow velocities in eyes with exudative AMD 3
months after intravitreal anti-VEGF antibody treatment
[30,31,32]. In this study, we demonstrated that the gene
expression was seen only in CNV area after intravenous injection
of the PIC micelles. Furthermore there were no apparent
histological abnormalities after intravenous injection of the PIC
micelles. Moreover, laboratory data showed no abnormal values in
physiological parameters under the current condition. This is in
contrast to our previous study that used systemic administration of
VEGF-selective RTK inhibitors in CNV model [33]. Thus, the
current results support that the nonviral gene therapy for
regulation of CNV using the PIC micelles have a great advantage
in several points. Firstly, intravenous injection deemed to be free of
ocular complications. Secondly, the gene expression is limited to
Figure 2. Targeted gene expression in the CNV area after intravenous injection of pYFP-PM. a: Choroidal flatmount and histological
analysis demonstrated YFP fluorescence in the CNV area after intravenous injection of pYFP-PM. b: Western blotting analysis demonstrated that YFP
protein was detected in the eyes with CNV, after intravenous injection of pYFP-PM. YFP expression was detected neither after generation of CNV
alone nor after intravenous injection of pYFP-PM without CNV. c: The results of immunohistochemistry demonstrated that the expression of F4/80
was partially overlapping the expression of YFP, indicating that YFP protein expressed in F4/80-positive macrophage. CNV: choroidal
neovascularization, pYFP-PM: the PIC micelles encapsulating pYFP (yellow fluorescent protein), PC: photocoagulation, bar:100 um.
doi:10.1371/journal.pone.0028560.g002
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retina is reduced compared to the current therapy, i.e.,
intravitreous injection of VEGF antagonist. Disruption of VEGF
signaling might be effective for CNV treatment. However, it may
also inhibit angiogenesis that is needed for vascular maintenance
and repair under normal conditions angiogenesis. Therefore, even
if blockage of VEGF signaling is effective in suppressing CNV
development, inhibition of VEGF signaling in the retina and other
organs, particularly those of advanced age, such as AMD patients,
may in fact be dangerous. In turn, our system presented here
clearly demonstrated target-tissue specific expression of pDNA,
and is expected to be used without systemic adverse effects as
described above. It is generally accepted that blockade of VEGF
signaling pathway leads to decreased macrophage infiltration,
although further studies are needed.
To put this treatment to clinically use, it is important to
investigate the most appropriate dose and dosing regimen,
although the current study employed multiple injection based on
our preliminary results and considering the fact that expression
level of the transferred gene was low when compared to viral
vectors.
In conclusion, we have explored the possibility of the treatment
of exudative AMD via systemic gene delivery utilizing the PIC
micelles encapsulating plasmid DNA. The obtained results have
demonstrated that the PIC micelles accumulated in CNV, thereby
exhibiting high therapeutic efficiency against mouse AMD model.
This study suggests the current system that blocks local VEGF by
the systemic gene therapy using the PIC micelles encapsulating
sFlt-1 has a potential as a novel anti-angiogenic treatment for
CNV.
Materials and Methods
Animals
Eight-week-old male C57 BJ/6 mice were purchased from
Saitama Laboratory Animal Supply Inc. (Saitama, Japan). All
animal experiments conformed to the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research for animal
use. All animal experiments were carried out in accordance with
the guidelines for animal experiments at the University of Tokyo,
Japan, and were approved by the Animal Care Committee of the
University of Tokyo. (approval No. med-p10-020)
All procedures were performed with the animals under general
anesthesia by administration of mixture (1.5 ml/kg) of keramin
hydrochloride (Ketalar, Sankyo, Tokyo, Japan) and xylazine
hydrochloride (Celactal, Bayer, Tokyo, Japan).
Preparation of PIC micelles encapsulating pDNA
A fragment cDNA of SEYFP-F46L, a variant of a yellow
fluorescent protein with the mutation F46L, provided by RIKEN
(Wako, Japan), was inserted into the pCAcc vector (pYFP) and a
fragment cDNA of human soluble Flt-1, provided by Dr. Masashi
Shibuya, was inserted into the pVL1393 vector (psFlt-1). PEG-b-
PAsp(DET) block copolymers and PAsp(DET) homopolymers
were synthesized as previously reported [15,16,17]. PIC micelles
encapsulating pDNA were prepared by mixing pDNA and a
mixture of PEG-b-PAsp(DET) and PAsp(DET) in 10 mM Hepes
buffer (pH 7.3) at the block copolymer/homopolymer ratio of 70/
30 on the basis of amine numbers and the N/P ratio (N= total
amines in polycations; P= total phosphate anions in pDNA) of 8
(pDNA concentration: 100 mg/mL) (Fig3).
Generation of CNV by laser photocoagulation
After the pupil was dilated with 1 drop of 0.5% tropicamide
(Mydrin M; Santen Pharmaceutical, Osaka, Japan), the CNV
lesions were induced by laser photocoagulation as has been
previously described [34]. A glass cover served as a contact lens.
Diode-laser (DC-3000, NIDEK, Osaka, Japan) and irradiation
was delivered through a slit lamp (SL150, Topcon, Tokyo, Japan).
The following laser parameters were used; spot size of 200 mm,
power of 100 mW, and exposure duration of 20 msec. One and
four lesions were created between the major retinal vessels in each
Table 1. Laboratory data.
AST(IU/L) ALT(IU/L) BUN(mg/dL)
creatinine
(mg/dL)
control 58.765.7 24.063.1 29.662.6 0.2160.01
PIC micelle 63.464.8 25.061.4 25.661.5 0.1960.02
doi:10.1371/journal.pone.0028560.t001
Figure 3. Intravenous injection of psFlt-1-PM decreased the area of CNV. Quantification of the CNV lesion demonstrated that the
neovascularized area in the mice that received psFlt-1-PM was significantly reduced by 60% than that of control mice (n=7, p,0.01), whereas the
administration of pYFP-PM had no significant effects on the neovascularized area. The lower panels show representative micrographs. Arrows
indicate the CNV lesion. CNV: choroidal neovascularization, psFlt-1-PM: the PIC micelle encapsulating psFlt-1 (fms-like tyrosine kinase-1), pYFP-PM: the
PIC micelles encapsulating pYFP (yellow fluorescent protein).
doi:10.1371/journal.pone.0028560.g003
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respectively. To test transfection efficacy, mice were assigned to
control or treatment group and received intravenous injection of
the PIC micelles encapsulating pYFP (pYFP-PM; n=10 in each
group). Each mouse received an intravenous injection of 200 mLo f
pYFP-PM or PBS 1, 3 and 5 days after laser photocoagulation.
Seven days after laser photocoagulation, the tansfection efficacy
was investigated by fluorescent microscopy and Western blot
analyses. For the analysis of the efficacy of the PIC micelles
encapsulating psFlt-1 (psFlt-1-PM), twenty mice (n=7 in each
group) were randomly assigned to psFlt-1-PM, or pYFP-PM or
control group. Each mouse received a intravenous injection of
200 mL of psFlt-1-PM, pYFP-PM or PBS 1, 3 and 5 days after
laser photocoagulation. CNV lesion size was investigated by
choroidal flatmount analysis.
In vivo detection of YFP
To investigate the transfection efficacy of the PIC micelles,
expression of YFP was examined by fluorescent microscopy using
RPE/choroidal flatmount analysis. The eyes were enucleated, and
cornea, lens, and vitreous were removed and the RPE/choroid
was separated and four radial cuts were made at the peripheral
choroid to the equator, and the RPE/choroid was flatmounted on
a slide with the vitreous side facing up. The flatmount were viewed
by fluorescent microscope with an YFP selective filter set
(excitation wavelength 500 nm, filter wavelength 530 nm).
Photographs were taken with the aid of a CCD camera. Samples
from mice with CNV but without treatment served as negative
controls, and showed no fluorescence under the current condi-
tions.
Immunostaining
Immunostaining was preformed essentially as described previ-
ously [34]. Briefly, seven days after laser photocoagulation, the
RPE-choroidal flatmount was made, and the sample was
incubated with rabbit polyclonal antibody against anti-F4/80
(Abcam) at a concentration of 1:100. Alexa525 conjugated
secondary antibody was used to visualize the immunostaining.
The samples were viewed with fluorescence microscope.
Western-blot analysis
Seven days after laser photocoagulation, the RPE/choroid
samples were lysed with ice-cold RIPA buffer (50 mM Tris-HCL
(PH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, and
1 mM EDTA). The lysates were centrifuged for 15 min at
14000rpm in a microcentrifuge. Protein content of the resultant
supernatants was measured by using BCA Protein assay kit.
Protein samples were dissolved in sample buffer at a concentration
of 1:1 and were resolved by SDS-PAGE and electroblotted onto a
polyvinylidene difluoride membrane. The membrane was placed
in blocking solution (5% nonfat dry milk in TBST) for one hour at
room temperature. The membranes were incubated overnight at
4uC with anti-YFP antibody (Abcam) at a concentration of 1:100.
The membranes were incubated with horseradish peroxidase
labeled second antibody (Amersham biosciences) at a concentra-
tion of 1:5000 for one hour at room temperature and were
developed with ECL Plus Western Blotting Detection Reagents
(General Electric Company).
Quantitative analysis of the CNV lesions
Choroidal flatmount analysis was performed to quantify the
CNV lesions and CNV was imaged by lectin angiography as has
been described elsewhere [34]. Mice received intravenous BS-1
lectin conjugated with FITC (Vector Laboratories, Burlingame,
CA) seven days after laser photocoagulation. Then the eyes were
enucleated, and the RPE/choroid samples prepared with
aforementioned method were flatmounted on a slide with the
vitreous side facing up. NIH Image was used for the image
analysis. The quantification of the CNV was performed in a
masked manner.
Statistical Analysis
The one-way analysis of variance (ANOVA) was used to
compare the CNV area. P values of less than 0.05 were considered
significant.
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